Crysalin Limited, a London and Oxford, UK-based biotechnology company developing a patented technology for protein structure determination, has completed a £1.55m funding.
Investors include IP Group, Oxford Technology Management and Oxford Spin-Out Equity Management.
Crysalin, which is a spin-out from the University of Oxford, develops products for the pharmaceutical and biotechnology industry, enabling protein structure determination where current methodologies have proved ineffective. Its patented lattice-based nanomaterials have demonstrated significant advantages in drug discovery and development over current methods.
The company intends to use the funds to further exemplify the technology’s drug discovery and development potential and rapidly bring the technology to market. Crysalin’s solution is based on research carried out by Professor Martin Noble and Dr John Sinclair at the University of Oxford’s Laboratory of Molecular Biophysics, part of the Department of Biochemistry.
The company also named David Brister as Chairman. Mr. Brister brings to Crysalin over twenty years experience in a variety of private equity, venture capital and operational roles.